share_log

Novavax | SC 13G: Statement of acquisition of beneficial ownership by individuals-Morgan Stanley(6.2%)

SEC announcement ·  Feb 9 14:05
Summary by Moomoo AI
Morgan Stanley has filed a Schedule 13G with the United States Securities and Exchange Commission on February 9, 2024, indicating a significant ownership stake in Novavax, Inc. As of December 31, 2023, Morgan Stanley reported shared voting power over 7,281,646 shares and shared dispositive power over 7,308,033 shares of Novavax common stock, representing 6.2% of the company's class of securities. The filing was made under Rule 13d-1(b), which is typically used by passive investors to report holdings. Morgan Stanley stated that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Morgan Stanley has filed a Schedule 13G with the United States Securities and Exchange Commission on February 9, 2024, indicating a significant ownership stake in Novavax, Inc. As of December 31, 2023, Morgan Stanley reported shared voting power over 7,281,646 shares and shared dispositive power over 7,308,033 shares of Novavax common stock, representing 6.2% of the company's class of securities. The filing was made under Rule 13d-1(b), which is typically used by passive investors to report holdings. Morgan Stanley stated that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more